Skip to main content

Advertisement

Table 5 Regression models for recrudescence and new infection using data from Burkina Faso (n = 810) [18]

From: Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis

  Observed proportion of events Cause-specific Cox proportional hazard model Fine and Gray’s sub-distribution hazard model
Cause-specific HR [95% confidence interval] P-value Sub-distribution HR [95% confidence interval] P-value
Model for recrudescence
 Age (/yearly increase) 4.9% (40/810) 0.99 [0.77–1.29] 0.965 1.00 [0.80–1.25] 0.990
 Baseline parasitaemia (/µL) (tenfold increase) 4.9% (40/810) 1.67 [0.88–3.16] 0.114 1.44 [0.84–2.46] 0.190
 Treatment (ref = DP) 3.2% (7/221)     
  AL 8.2% (24/294) 4.02 [1.72–9.43] 0.001 2.85 [1.24–6.57] 0.014
  ASAQ 3.1% (9/295) 1.12 [0.42–2.99] 0.829 1.01 [0.38–2.69] 0.980
Model for new infection
 Age (/yearly increase) 29.4% (238/810) 1.08[0.98–1.21] 0.121 1.08[0.99–1.19] 0.093
 Baseline parasitaemia (/µL) (tenfold increase) 29.4% (238/810) 1.52[1.18–1.97] 0.001 1.40[1.10–1.78] 0.006
 Treatment (ref = DP) 10.0% (22/221)     
  AL 48.3% (142/294) 8.05[5.12–12.67] < 0.001 6.51[4.27–9.94] < 0.001
  ASAQ 25.1% (74/295) 3.03[1.88–4.88] < 0.001 2.83[1.80–4.44] < 0.001
  1. AL artemether–lumefantrine, DP dihydroartemisinin–piperaquine, ASAQ artesunate–amodiaquine